Biomarker & Intervention Discovery

ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Spontaneous remissionFull recovery without intervention: <5% of adult ME/CFS patients; partial improvement in ~40% over 5 years; post-COVID…
Best-intervention remissionNo disease-modifying treatment established; GET (graded exercise therapy) — former standard — shown harmful (PACE…
Gap sizeVery large — no effective treatment; historic misattribution to psychological causes delayed research by decades
Primary barrierbiological (no treatment) + framing (historic)
Full remission profile →

Remission & chronicity

Spontaneous remission
Full recovery without intervention: <5% of adult ME/CFS patients; partial improvement in ~40% over 5 years; post-COVID ME/CFS appears to have similarly low spontaneous recovery rate
Best-intervention remission
No disease-modifying treatment established; GET (graded exercise therapy) — former standard — shown harmful (PACE controversy, withdrawn from UK NICE guidance 2021); pacing (heart rate-based) prevents post-exertional malaise but not curative; low-dose naltrexone — ~30% improvement in small RCTs; rintatolimod (Ampligen) — Phase 3 failed FDA approval
Gap size
Very large — no effective treatment; historic misattribution to psychological causes delayed research by decades
Primary barrier
biological (no treatment) + framing (historic)
ME/CFS research has been systematically underfunded relative to disease burden (NIH funding $15M/year vs MS at $100M despite similar prevalence); PACE trial's GET/CBT approach adopted globally for years despite being harmful for many patients; NIH RECOVER initiative now represents largest-ever investment
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 0-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.